Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

• Published in: Rheumatic & musculoskeletal diseases open Vol. 10; no. 2; p. e003912
• Main Authors: Buch, Maya H, Bhatt, Deepak L, Charles-Schoeman, Christina, Giles, Jon T, Mikuls, Ted, Koch, Gary G, Ytterberg, Steven, Nagy, Edward, Jo, Hyejin, Kwok, Kenneth, Connell, Carol A, Masri, Karim Richard, Yndestad, Arne
• Format: Journal Article
• Language: English
• Published: England EULAR 12.04.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Antirheumatic Agents; Arthritis, Rheumatoid; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Cardiovascular Diseases; Heart Failure; Humans; Myocardial Infarction - epidemiology; Myocardial Infarction - etiology; Piperidines - adverse effects; Pyrimidines; Rheumatoid arthritis; Skin cancer; Therapeutics; Thromboembolism; TNF inhibitors; Transient ischemic attack; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; United States > US; Antirheumatic Agents; Tumor Necrosis Factor Inhibitors; Cardiovascular Diseases; Arthritis, Rheumatoid; Therapeutics
• ISSN: 2056-5933; 2056-5933
• DOI: 10.1136/rmdopen-2023-003912

ObjectivesCompare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance.MethodsPatients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. MACE (non-fatal myocardial infarction (MI), non-fatal stroke or CV death (MACE-3)) was extended by sequential addition of CV events (hospitalisation for unstable angina (MACE-4), coronary revascularisation (MACE-5), transient ischaemic attack (MACE-6), peripheral vascular disease (MACE-7)), heart failure (HF) hospitalisation (MACE-8) and venous thromboembolism (VTE; (MACE-8 plus VTE)). HRs (tofacitinib vs TNFi) were evaluated for MACE and individual components.ResultsHRs for MACE-4 to MACE-8 with combined and individual tofacitinib doses versus TNFi were similar. Risk of MACE-8 plus VTE appeared similar with tofacitinib 5 mg two times per day versus TNFi (HR 1.12 (0.82 to 1.52)), but higher with tofacitinib 10 mg two times per day versus TNFi (HR 1.38 (1.02 to 1.85)). Risk of MI was higher with tofacitinib versus TNFi, but difference in risk of other individual CV events was not suggested. Across extended MACE definitions, risk appeared higher with tofacitinib versus TNFi in those with atherosclerotic CV disease or age ≥65 years.ConclusionIn ORAL Surveillance, risk of composite CV endpoints combining all ischaemic CV events and HF did not appear different with tofacitinib versus TNFi. The totality of CV risk was higher with tofacitinib 10 mg two times per day versus TNFi, driven by an increase in VTE.Trial registration number NCT02092467.